Quantification of human cytomegalovirus using bronchoalveolar lavage cells in pulmonary complications associated with hematologic neoplasia

  • Authors:
    • Junko H. Ohyashiki
    • Akira Nagate
    • Tomoko Ojima
    • Kenji Abe
    • Kohtaro Yamamoto
    • Kazuma Ohyashiki
  • View Affiliations

  • Published online on: June 1, 2003     https://doi.org/10.3892/ijmm.11.6.779
  • Pages: 779-783
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Human cytomegalovirus (CMV) has been recognized as a frequent pathogen involved in interstitial pneumonia (IP), and CMV-IP is a severe and life-threatening complication in the immunocompromised patients. The use of real-time PCR in molecular diagnostics has increased to the point where it is now accepted as the gold standard for detecting a wide variety of templates including viruses. Therefore, we developed a rapid quantification system of CMV using a LightCycler in order to clarify the possible role of CMV reactivation in patients with hematologic neoplasia showing pulmonary complications. Sixty-nine bronchoalveolar lavage fluid (BALF) specimens were obtained from consecutively treated patients showing interstitial shadow including 20 patients with hematologic neoplasia. First, we determined the viral burden in BAL cells from healthy volunteers, idiopathic interstitial pneumonia (IIP) and sarcoidosis. CMV copy numbers in samples obtained from healthy volunteers, IIP and sarcoidosis, were less than 102 copies per 1 μg of DNA, whether or not BAL cells were composed of high percentage of lymphocytes. Among 20 patients with hematologic neoplasia analyzed, two specimens obtained from leukemia patients with pulmonary alveolar proteinosis, two from GvHD, one with CMV interstitial pneumonia and one with Hodgkin's disease had high level of CMV viral DNA. Our results suggest that measurement of CMV genomes in BAL cells using real-time PCR may be useful not only to understand the involvement of CMV in systematic respiratory tract disease but also in management of the care of respiratory complications in hematologic neoplasia.

Related Articles

Journal Cover

June 2003
Volume 11 Issue 6

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ohyashiki JH, Nagate A, Ojima T, Abe K, Yamamoto K and Ohyashiki K: Quantification of human cytomegalovirus using bronchoalveolar lavage cells in pulmonary complications associated with hematologic neoplasia. Int J Mol Med 11: 779-783, 2003
APA
Ohyashiki, J.H., Nagate, A., Ojima, T., Abe, K., Yamamoto, K., & Ohyashiki, K. (2003). Quantification of human cytomegalovirus using bronchoalveolar lavage cells in pulmonary complications associated with hematologic neoplasia. International Journal of Molecular Medicine, 11, 779-783. https://doi.org/10.3892/ijmm.11.6.779
MLA
Ohyashiki, J. H., Nagate, A., Ojima, T., Abe, K., Yamamoto, K., Ohyashiki, K."Quantification of human cytomegalovirus using bronchoalveolar lavage cells in pulmonary complications associated with hematologic neoplasia". International Journal of Molecular Medicine 11.6 (2003): 779-783.
Chicago
Ohyashiki, J. H., Nagate, A., Ojima, T., Abe, K., Yamamoto, K., Ohyashiki, K."Quantification of human cytomegalovirus using bronchoalveolar lavage cells in pulmonary complications associated with hematologic neoplasia". International Journal of Molecular Medicine 11, no. 6 (2003): 779-783. https://doi.org/10.3892/ijmm.11.6.779